We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Bribery serves as life-support for Chinese hospitals

Tue, 23rd Jul 2013 21:00

* Low salaries foster widespread bribery in public hospitals

* State fixes cost of hospital operations and caps drugprices

* Leaves public hospitals with little room to top updoctors' pay

* Britain's GlaxoSmithKline embroiled in bribery scandal

By Kazunori Takada

SHANGHAI, July 24 (Reuters) - Bribery is the lubricant thathelps keep China's public hospitals running, and the healthsystem would struggle to function without illegal payments topoorly paid doctors and administrators, say medicalpractitioners and industry experts.

They say government policies are partly to blame for asystem in which doctors and other staff expect to be paid extrafees to perform operations and take kickbacks frompharmaceutical firms and medical-equipment suppliers.

The profession's ugly underbelly was exposed last week whenpolice accused British drugmaker GlaxoSmithKline ofbribing officials and doctors for six years to boost sales andthe price of its medicines. GSK has called the developments"shameful" and on Monday said some of its Chinese executivesappeared to have broken the law.

China is an appealing market for pharmaceutical firms andmedical-equipment makers, with spending in the industry expectedto nearly triple to $1 trillion by 2020 from $357 billion in2011, according to consulting firm McKinsey.

The corruption stems largely from doctors' low basesalaries, which are set in line with a pay scale for governmentworkers. Hospitals can pay bonuses but, given public hospitalsare strapped for cash, compensation is usually low, say doctorsand industry experts.

A doctor fresh out of medical school in Beijing earns about3,000 yuan ($490) a month including bonuses -- roughly the sameas a taxi driver. A doctor with 10 years experience makes around10,000 yuan a month, according to Peter Chen, chief executive ofprivately run Oasis International Hospital in Beijing.

"Without the grey income, doctors would not have theincentive to practise," said Yanzhong Huang, a senior fellow forglobal health at the Council on Foreign Relations in New York.

CAN'T SURVIVE ON SALARIES

Over the past 30 years the Chinese government has made itshealthcare sector more market-oriented. That means the country's 13,500 public hospitals have to balance their own books.

Medical services accounted for just over 50 percent ofpublic hospital revenue in 2011, according to Health Ministrydata. About 40 percent came from prescribing drugs while therest was from other income as well as government subsidies,which have fallen steadily since the 1980s.

Hospital administrators can set fees for in-patient care,nursing and laboratory tests. But the state fixes the cost ofoperations to make surgery affordable to ordinary Chinese. Andit effectively caps the cost of many prescribed medicines bysetting a suggested price.

That leaves hospitals little room to top up wages.

One Chinese doctor who used to hold a senior position at aprominent hospital in Beijing said 80 percent of his income camefrom bribes. Without it, he would have earned less than $600 amonth, said the doctor, who left China five years ago to live inBritain where he continues practising medicine.

"These sums (bribes) are essential. You cannot survive onyour salary," said the 50-year-old physician, who spoke oncondition of anonymity due to the sensitivity of the issue.

An industry executive who has worked in China's medicalsector for more than 15 years said bribery and corruptionpermeated every level of a public hospital.

"They are seen as necessities in the current healthcaresystem," said the executive, who also declined to be identified.

The Health Ministry did not respond to a request forcomment. Officials at the National Development and ReformCommission, which sets the prices of prescribed medicines, alsodeclined to comment.

Low base salaries are a legacy of China's planned economy,said Jia Xijin, associate professor at the School of PublicPolicy and Management at Tsinghua University in Beijing,explaining the dilemma faced by the government.

China has also committed to making health care affordablefor its 1.37 billion people. The government has spent 2.2trillion yuan ($358 billion) on the system since 2009, of whichmore than 680 billion yuan was to provide universal healthinsurance coverage, state media quoted the Finance Ministry assaying earlier this year.

RED ENVELOPES

Public hospitals say recruiting new doctors is gettingharder as many physicians are turned off by the wages at a timewhen patient numbers are growing. Health Ministry data showedthe overall number of doctors rose 13 percent from 2008 to 2011,while patient visits jumped 28 percent.

"There will be no doctors left to treat the current doctorswhen they retire," said the accounting director at a Shanghaihospital who declined to be identified because she was notauthorised to speak to the media.

Low salaries have also spawned a system of under-the-tablepayments from patients. The payments are known as "hongbao" -- areference to the cash-filled red envelopes given as presentsduring Lunar New Year festivities -- and cover various servicesfrom jumping the queue for appointments to extra surgical fees.

Bob Wang, a 35-year-old businessman in Beijing, said he gavethe main surgeon who operated on his aunt's femur bonetransplant last year 5,000 yuan in "hongbao" on top of the100,000 yuan he paid to the hospital because he was worried thedoctor would not take the operation seriously otherwise.

There was unstated "hongbao" guidance for each type ofsurgery, he said.

"If my family or myself get sick ... we won't just go to thehospital. Everything will take forever -- from registration towaiting for a bed, to getting seen by a doctor to queuing forsurgery," he said.

According to the doctor now living in Britain, patients andtheir families could sometimes spend two to three times morethan the actual fee in "hongbao".

Critics doubt that an anti-corruption campaign by PresidentXi Jinping will have much impact.

Indeed, a former doctor at a major heart hospital in Beijingsaid eradicating corruption would be nearly impossible.

"It would be easy to find out who was taking money if thegovernment wanted to," said the cardiologist, who has beenworking in the United States since 2009.

"But everyone would be found guilty. How could the hospitalssurvive?"

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.